Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Rheumatology · AA Amyloidosis

How Does Chronic Inflammation Cause AA Amyloidosis?

At a Glance

AA amyloidosis develops when long-term inflammation keeps a blood protein called Serum Amyloid A (SAA) high. Misfolded SAA fragments form deposits, often in the kidneys, so controlling inflammation and monitoring kidney function are central to care.

In this answer

4 sections

01

The Role of Serum Amyloid A (SAA)

02

From Normal Protein to Amyloid Deposits

03

How Amyloid Deposition Affects Your Kidneys

04

Stopping the Process at the Source

If you have a chronic inflammatory disease like rheumatoid arthritis, your body is in a persistent state of alarm. This ongoing inflammation causes your liver to overproduce a defense protein called Serum Amyloid A (SAA) [1]. Over years, if this inflammation remains high, fragments of SAA can misfold and form abnormal structures called amyloid fibrils [2]. These fibrils accumulate as deposits in your organs—most often the kidneys—causing a condition called AA amyloidosis [3].

There are many types of amyloidosis; AA amyloidosis specifically refers to the type driven by long-term inflammatory conditions, setting it apart from other forms like AL or transthyretin (ATTR) amyloidosis [4].

The Role of Serum Amyloid A (SAA)

When your body detects inflammation—whether from an autoimmune disease like rheumatoid arthritis, a chronic infection, or an inherited condition like Familial Mediterranean Fever—it releases inflammatory signals called cytokines [4][5]. Cytokines are small proteins that help immune cells communicate. Interleukin-6 (IL-6), along with other cytokines like IL-1 and TNF, act as alarm messengers that stimulate your liver [6][7].

In response to these signals, the liver pumps out large amounts of Serum Amyloid A (SAA) [1]. SAA is a “positive acute-phase protein,” meaning its levels rise in response to inflammation. In a healthy, temporary immune response, SAA levels rise briefly and then return to normal. However, in chronic inflammatory diseases, SAA levels can remain abnormally high for months or years [6][8].

From Normal Protein to Amyloid Deposits

Prolonged high SAA levels increase the risk of amyloidosis, though it does not happen to everyone. Genetics, how your body processes proteins, and your natural waste-clearing systems all affect your individual risk [5][9].

When there is an oversupply of SAA, fragments of the protein can change their physical shape [2]. These modified pieces misfold and snap together to form rigid, thread-like structures called amyloid fibrils [10][11]. Because these fibrils are abnormally shaped, your body cannot easily break them down, leading them to accumulate as deposits in your tissues over time [12][3].

How Amyloid Deposition Affects Your Kidneys

For reasons that are not entirely understood, AA amyloid deposits have a strong tendency to form in the kidneys [13].

The kidneys act as your body’s filtration system. As amyloid deposits build up in the kidney’s delicate filters, they disrupt normal filtration [14]. This damage often leads to nephrotic syndrome, a condition characterized by large amounts of essential proteins leaking into your urine, often accompanied by low protein levels in your blood and noticeable swelling (edema) [13][15].

Kidney involvement can be silent at first, so relying on symptoms like foamy urine or swelling is not enough. Doctors monitor for kidney disease using routine tests like urine protein-to-creatinine ratios, estimated glomerular filtration rate (eGFR), and blood pressure checks [16]. Over time, ongoing deposition can lead to chronic kidney disease [3][14]. However, kidney failure is not inevitable; sustained control of inflammation can stabilize the disease [16].

While the kidneys are the main concern, AA amyloid can sometimes deposit in less common extra-renal sites like the digestive tract, liver, or spleen [17]. Very rarely, it can affect the heart or thyroid, though cardiac involvement is much less common in AA than in other types of amyloidosis [18].

Stopping the Process at the Source

Controlling your underlying inflammation is the main modifiable factor in treating AA amyloidosis [7][19]. Treating the root cause—such as adjusting rheumatoid arthritis therapies—reduces the inflammatory signals to the liver [4]. You should never stop or alter your immunosuppressive medications without consulting your rheumatologist.

When treatment successfully lowers these signals, the liver produces less SAA, which reduces the formation of new amyloid deposits [6][20]. Achieving and maintaining consistently low levels of SAA may stabilize organ function and, in some cases, allow existing deposits to slowly regress, though existing kidney damage may not fully reverse [19][20].

Common questions in this guide

What causes AA amyloidosis?
AA amyloidosis is caused by long-term inflammation from conditions such as rheumatoid arthritis, chronic infections, or Familial Mediterranean Fever. Inflammation signals the liver to make excess Serum Amyloid A (SAA); over time, SAA fragments can misfold and form amyloid deposits.
Why does AA amyloidosis often affect the kidneys?
AA amyloid deposits can build up in the kidneys’ filtering units and interfere with filtration. This may cause protein to leak into urine, swelling, nephrotic syndrome, and eventually chronic kidney disease.
Can high SAA levels cause AA amyloidosis in everyone?
No. Persistently high SAA increases risk, but genetics, protein processing, waste-clearing systems, and the duration of inflammation also affect whether deposits form.
Can treating inflammation slow or reverse AA amyloidosis?
Effective treatment that lowers inflammation and SAA can reduce formation of new amyloid deposits and may stabilize organ function. Existing kidney damage may not fully reverse, so do not stop or alter immunosuppressive medicines without guidance from your clinician.
What tests check for kidney problems from AA amyloidosis?
Doctors commonly monitor the urine protein-to-creatinine ratio, eGFR, and blood pressure, and may measure SAA to track inflammation. Kidney involvement can be silent, so testing matters even without foamy urine or swelling; a tissue biopsy may be used to confirm and type amyloidosis.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Related questions

When Should Family Members Get hATTR Genetic Testing? What Is Amyloidosis Life Expectancy With New Treatments? How Is Peripheral Neuropathy Pain Treated in Amyloidosis? Why Does Amyloidosis Cause GI Symptoms and Dizziness? ATTR Stabilizers vs. Silencers: What's the Difference?
Show more
Why Beta-Blockers Can Be Risky in Cardiac Amyloidosis? What Are the Risks of Misdiagnosing ATTR vs AL Amyloidosis? What Are Dry Weight and Fluid Limits in Cardiac Amyloidosis? How Early Can Carpal Tunnel Signal Cardiac Amyloidosis? How Do Doctors Monitor Amyloidosis Treatment Response? How Do I Transfer Amyloidosis Slides for a Second Opinion? What Is ALECT2 Amyloidosis and Who May Be at Risk?

Get notified when new evidence is published on Amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current Serum Amyloid A (SAA) level, and what is our target goal?
  2. 2.Are my current medications effectively controlling the underlying inflammation driving my risk for AA amyloidosis?
  3. 3.What are my current eGFR and urine protein levels, and how often should we be testing them?
  4. 4.Was my diagnosis confirmed and typed via a tissue biopsy, and is a referral to a nephrologist appropriate?
  5. 5.How can my rheumatologist and nephrologist coordinate my care to manage both my arthritis and kidney health?

References

References (20)
  1. 1

    Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo.

    Ranganath S, Bhandari A, Avitahl-Curtis N, et al.

    PloS one 2015; (10(11)):e0141330 doi:10.1371/journal.pone.0141330.

    PMID: 26555695
  2. 2

    Amyloid A Amyloidosis.

    Gaffney PM

    Veterinary pathology 2017; (54(1)):5-8 doi:10.1177/0300985816677150.

    PMID: 27879441
  3. 3

    Primary Sclerosing Cholangitis and Amyloid A Amyloidosis: Association or Coincidence?

    Lacetera R, Roggero L, Vercelloni P, et al.

    Case reports in nephrology and dialysis 2022; (12(3)):178-184 doi:10.1159/000524665.

    PMID: 36518362
  4. 4

    Amyloid A amyloidosis in a patient with Caplan's syndrome, with special reference to genetic predisposition.

    Nakamura T, Shiraishi N, Morikami Y, et al.

    Modern rheumatology case reports 2020; (4(2)):212-217 doi:10.1080/24725625.2020.1749361.

    PMID: 33087017
  5. 5

    Characteristics and course of patients with AA amyloidosis: single centre experience with 174 patients from Turkey.

    Bektas M, Koca N, Oguz E, et al.

    Rheumatology (Oxford, England) 2024; (63(2)):319-328 doi:10.1093/rheumatology/kead465.

    PMID: 37738242
  6. 6

    AA amyloidosis - Benefits and prospects of IL-6 inhibitors.

    Okuda Y

    Modern rheumatology 2019; (29(2)):268-274 doi:10.1080/14397595.2018.1515145.

    PMID: 30132351
  7. 7

    Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.

    Varan Ö, Kucuk H, Babaoglu H, et al.

    Modern rheumatology 2019; (29(2)):363-366 doi:10.1080/14397595.2018.1457469.

    PMID: 29578360
  8. 8

    The potential role of serum amyloid A as biomarker of rheumatic diseases: a systematic review and meta-analysis.

    Zinellu A, Mangoni AA

    Clinical and experimental medicine 2024; (24(1)):141 doi:10.1007/s10238-024-01413-0.

    PMID: 38951267
  9. 9

    Serum Amyloid A1 Induces Classically Activated Macrophages: A Role for Enhanced Fibril Formation.

    Gaiser AK, Bauer S, Ruez S, et al.

    Frontiers in immunology 2021; (12()):691155 doi:10.3389/fimmu.2021.691155.

    PMID: 34276683
  10. 10

    Influences of amino-terminal modifications on amyloid fibril formation of human serum amyloid A.

    Tanaka M, Takarada T, Nadanaka S, et al.

    Archives of biochemistry and biophysics 2023; (742()):109615 doi:10.1016/j.abb.2023.109615.

    PMID: 37105512
  11. 11

    Signal peptide stabilizes folding and inhibits misfolding of serum amyloid A.

    Wu JL, Chen YR

    Protein science : a publication of the Protein Society 2022; (31(12)):e4485 doi:10.1002/pro.4485.

    PMID: 36309973
  12. 12

    The inflammasome adaptor protein ASC promotes amyloid deposition in cryopyrin-associated periodic syndromes.

    Alarcón-Vila C, Hurtado-Navarro L, Mateo SV, et al.

    EMBO molecular medicine 2025; (17(1)):41-53.

    PMID: 39639164
  13. 13

    Renal amyloid A amyloidosis as a complication of hidradenitis suppurativa.

    Schandorff KD, Miller IM, Krustrup D, et al.

    Clinical nephrology 2016; (86(1)):51-4 doi:10.5414/cn108787.

    PMID: 27340120
  14. 14

    Systemic Amyloidosis with Renal Failure: A Challenging Diagnosis of SAPHO Syndrome.

    Correia CP, Martins A, Oliveira J, et al.

    European journal of case reports in internal medicine 2019; (6(4)):001087 doi:10.12890/2019_001087.

    PMID: 31139585
  15. 15

    Nephrotic Syndrome in a Retroviral Disease Due to AA Amyloidosis: A Rare Presentation.

    Kashiv P, Dubey S, Sejpal KN, et al.

    Cureus 2023; (15(9)):e44928 doi:10.7759/cureus.44928.

    PMID: 37818496
  16. 16

    Clinical profile and outcome of AA amyloidosis associated kidney disease in India.

    Bansal B, Sarkar A, Barwad A, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2026; (33(1)):15-24 doi:10.1080/13506129.2025.2573233.

    PMID: 41204056
  17. 17

    Early-onset gastrointestinal amyloid A amyloidosis without renal involvement in a patient with RA-pSpA overlap: A case report.

    Kwon HC

    Medicine 2025; (104(48)):e46291 doi:10.1097/MD.0000000000046291.

    PMID: 41327725
  18. 18

    A rare clinical case of systemic AA amyloidosis with cardiac involvement complicating ankylosing spondylitis: a case report.

    Barakat L, Echchilali K, Moudatir M, et al.

    The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology 2024; (76(1)):40 doi:10.1186/s43044-024-00471-9.

    PMID: 38546927
  19. 19

    Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study.

    Esatoglu SN, Hatemi G, Ugurlu S, et al.

    Medicine 2017; (96(34)):e7859 doi:10.1097/MD.0000000000007859.

    PMID: 28834898
  20. 20

    Prognostication of survival and progression to dialysis in AA amyloidosis.

    Palladini G, Riva E, Basset M, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2017; (24(sup1)):136-137 doi:10.1080/13506129.2017.1289917.

    PMID: 28434292

This page is for informational purposes only and does not constitute medical advice. Ask your rheumatologist or nephrologist about your inflammation control, kidney tests, and treatment plan.